The licenses will provide Enigma full access under patents owned or licensed by Roche Molecular Systems and its affiliates to practice HybProbe real-time polymerase chain reaction (PCR) chemistry.
They will also allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis, complementing the company’s existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.
Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and methicillin-resistant Staphylococcus aureus. These tests will be combined with Enigma’s fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.